Sa1213 An Analysis of Crohn's Disease Over the Past Decade in the United States Related to Cost of Hospitalization, Outcome, Length of Stay and Demographics

Abstract

maintenance infusion and 10.1% of patients received maintenance infusions on average more than one week late. A patient would be expected to accrue a dropped infliximab maintenance dose every 13.9 infusions (112.0 weeks) based on the standard maintenance regimen of infliximab 5mg/kg every eight weeks. However, among the 20 patients experiencing a mean delay in administration of infliximab of over 7 days, a dropped infliximab maintenance dose would be accrued every 33.3 weeks. As a percentage of time on maintenance infliximab, mean cumulative non-adherence was 6.1% (± 5.6%). In multivariate logistic regression analysis, only male gender (OR 1.77 [95% CI 1.01-3.11]) was predictive of non-adherence. Conclusions: While three quarters of patients are adherent with infliximab induction therapy, less than one third remain closely adherent to their maintenance infliximab infusion schedule. This non-adherence may have significant clinical implications for maintenance of remission and eventual secondary loss of response. Table 1: Baseline Patient Demographics and Adherence to Infliximab Therapy